Alfacalcidol Soft Capsules

Alfacalcidol is rapidly converted into 1,25-dihydroxyvitamin D3 in the liver. The latter is a metabolite of vitamin D3 and plays a role in regulating calcium and phosphate metabolism. Since this conversion process is very rapid, the clinical effects of alfacalcidol are basically the same as those of 1,25-dihydroxyvitamin D3. Its main function is to increase the level of 1,25-dihydroxyvitamin D3 in the blood circulation, thereby increasing the intestinal absorption of calcium and phosphate, promoting bone mineralization, reducing plasma parathyroid hormone levels, and reducing bone calcium dissolution, ultimately relieving bone and muscle pain and improving osteoporosis caused by intestinal calcium absorption disorders caused by menopause, aging and endocrine changes.

Main ingredients: The main ingredient of this product is alfacalcidol. Chemical name: 9,10-openedocholesterol-5,7,10(19)-triene-1α,3β-diol.

This product is a soft capsule, the contents of which are light yellow to dark yellow oily liquid.

1. Rickets and osteomalacia. 2. Renal osteodystrophy. 3. Osteoporosis. 4. Hypoparathyroidism.

Oral. Adjust the dosage under close monitoring according to the patient's serum calcium concentration. 1 Chronic renal insufficiency and osteoporosis: Adults once a day, 0.5-1.0μg (2-4 tablets) each time. Appropriate increase or decrease according to age and symptoms. 2 Hypoparathyroidism and other vitamin D metabolism disorders: Adults once a day, 1.0-4.0μg (4-16 tablets) each time. Appropriate increase or decrease according to age, disease, and symptoms. 3 Pediatric medication: Once a day. The oral dose for osteoporosis is 0.01-0.03μg/kg body weight, and the oral dose for other diseases is 0.05-1.0μg/kg body weight, which can be appropriately increased or decreased according to the disease and symptoms.

1 Serious adverse reactions (frequency unknown) (1) Acute renal failure: Since acute renal failure accompanied by increased serum calcium has occurred, serum calcium levels and renal function should be regularly observed. If abnormalities are found, appropriate measures such as discontinuation of the drug should be taken. (2) Abnormal liver function, jaundice: Since abnormal liver function and jaundice accompanied by increased AST (GOT), ALT (GPT), and AL-P values have occurred, careful observation should be made. If abnormalities are found, the drug should be discontinued and properly handled. 2 Other adverse reactions (frequency unknown) (1) Digestive system: loss of appetite, nausea, constipation, stomach pain, vomiting, abdominal distension, stomach discomfort, indigestion, abnormal sensation in the mouth, mouth

1. Contraindicated in patients with hypercalcemia, hyperphosphatemia (except those with hypoparathyroidism), and hypermagnesemia. 2. Symptoms of vitamin D poisoning. Patients who are allergic to any ingredient in this product or are known to be allergic to vitamin D and its analogs should not take alfacalcidol.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: Not yet clear. Precautions for the elderly: Not yet clear.

1 Calcium supplements: Combination with calcium supplements may cause elevated blood calcium, so blood calcium should be monitored. 2 Thiazide diuretics: This type of diuretic can promote the kidney's absorption of calcium. There is a risk of hypercalcemia when used together. 3 Digitalis glycosides: Hypercalcemia in patients taking digitalis drugs can easily induce arrhythmias. If this drug is used in combination, blood calcium should be closely monitored. 4 Barbiturates, anticonvulsants: These drugs can accelerate the metabolism of active vitamin D metabolites in the liver and reduce the efficacy of the drug, so the dose of this drug should be appropriately increased. 5 Gastrointestinal absorption inhibitors: Cholestyramine or aluminum-containing antacids can reduce the absorption of this drug. The two should not be taken at the same time. The drugs should be taken one after the other with an interval of 2 hours. <b

Keep away from light, seal tightly, and store in a cool, dark, and dry place. Valid for 24 months.

0.25 μg

36 months

China Resources Double-Crane Pharmaceutical Co., Ltd.

• Founded in:

  1997-05-16

• Address:

  No. 1, Lize East 2nd Road, Wangjing, Chaoyang District, Beijing

• Tax NO.:

  91110000633796475U

• Registered Funds:

  1,038,836,522 yuan

• Website:

  Log in to view

• Email:

  Log in to view